Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress

Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH) will present data at the 15th Annual European Epilepsy Congress in Rome, Italy, from September 7-11, 2024. The company will showcase late-breaking and encore data on bexicaserin, their novel treatment for Developmental and Epileptic Encephalopathies (DEEs).

Key presentations include:

• Interim results from the PACIFIC study open-label extension on bexicaserin's safety and tolerability
• Efficacy and safety results from the Phase 1b/2a PACIFIC study
• Data on bexicaserin's minimal drug interaction potential
• Phase 1 study results showing robust brain penetration and receptor engagement
• Preclinical data demonstrating broad antiepileptic activity

This conference participation aligns with Longboard's preparations for initiating their global Phase 3 program later this year.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data at the International League Against Epilepsy (ILAE) 15^th Annual European Epilepsy Congress which is taking place in Rome, Italy from September 7-11, 2024.

“ILAE is one of the premier medical organizations in the epilepsy space and we look forward to participating in this important meeting, which brings together key opinion leaders from across Europe and the rest of world. As we prepare for the initiation of our global Phase 3 program this year, this conference will help us continue to broaden our engagement with potential investigators and gain important insights,” stated Dr. Randall Kaye, Longboard’s Chief Medical Officer. “We are pleased that our PACIFIC study open label extension interim data was accepted as a late breaker for this conference, and we look forward to discussing these data as well as additional data that highlights the potential of bexicaserin for individuals living with a broad range of Developmental and Epileptic Encephalopathies, or DEEs.”

EVENT DETAILS:

LATE BREAKER
Title: Safety and Tolerability of Bexicaserin in Adolescents and Adults with Developmental and Epileptic Encephalopathies: Interim Results of the Phase 1b/2a PACIFIC Study Open-Label Extension (OLE)
Event Type: In-Person Posters
Poster Number: P082

Title: Efficacy and Safety of Bexicaserin (LP352) in Adolescent and Adult Participants with Developmental and Epileptic Encephalopathies: Results of The Phase 1b/2a PACIFIC Study
Session: Platform Session – Drug Therapy
Event Type: Platform Session
Presentation Time: Sunday, September 8, 2024, from 12:30 PM – 12:38 PM CET

Title: Bexicaserin has Negligible CYP Or P-glycoprotein Interaction Potential, Minimizing Therapeutic Complexity In Epilepsy Patients with a High Burden of Polypharmacy
Event Type: In-Person Posters
Poster Number: P321

Title: A Phase 1 Study Of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics and QEEG Changes Reflecting Receptor Engagement
Event Type: In-Person Posters
Poster Number: P262

Title: Bexicaserin, A 5-HT2C Superagonist, has Broad Antiepileptic Activity in Preclinical Seizure Models
Event Type: In-Person Posters
Poster Number: P261

ABOUT LONGBOARD PHARMACEUTICALS

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age and older. Earlier this year, Longboard reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants with DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. Longboard recently completed a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Bexicaserin and LP659 are investigational compounds that are not approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. In some cases, you can identify forward-looking statements by words such as “focus”, “will”, “look forward to”, “prepare for”, “potential”, “working to”, “designed to”, “plans”, “potential” or the negative, plural or other tenses of these words, references to future dates or time periods, or other comparable language, and they may include, without limitation, statements about Longboard’s presentations, product candidates, clinical and preclinical programs, focus and work. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240826889335/en/

Megan E. Knight

VP, Head of Investor Relations

IR@longboardpharma.com

858.789.9283

Source: Longboard Pharmaceuticals, Inc.

FAQ

What data will Longboard Pharmaceuticals (LBPH) present at the 15th European Epilepsy Congress in 2024?

Longboard Pharmaceuticals will present late-breaking and encore data on bexicaserin for Developmental and Epileptic Encephalopathies (DEEs). This includes interim results from the PACIFIC study open-label extension, efficacy and safety data from the Phase 1b/2a PACIFIC study, and information on bexicaserin's drug interaction potential and brain penetration.

When and where will the 15th European Epilepsy Congress take place?

The 15th European Epilepsy Congress will take place in Rome, Italy, from September 7-11, 2024.

What is the significance of Longboard Pharmaceuticals (LBPH) participating in this epilepsy congress?

Participation in this congress allows Longboard Pharmaceuticals to engage with key opinion leaders, potential investigators, and gain insights as they prepare to initiate their global Phase 3 program for bexicaserin later in the year.

What is bexicaserin and what condition is it being developed to treat?

Bexicaserin (LP352) is a 5-HT2C superagonist being developed by Longboard Pharmaceuticals (LBPH) to treat Developmental and Epileptic Encephalopathies (DEEs), a broad range of severe epilepsy disorders.

What are some key findings about bexicaserin that Longboard Pharmaceuticals (LBPH) will present at the congress?

Key findings include bexicaserin's safety and tolerability in DEE patients, its efficacy in the PACIFIC study, minimal drug interaction potential, robust brain penetration, and broad antiepileptic activity in preclinical models.